1Meier J[J]. The contribution of incretin hormones to the patho- genesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2009;23(4) :433 -441.
2Vilsboll T,Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon - like peptide 1 in type 2 diabetic patients. Diabetes 2001 ;50(3) :609 -613.
3Vilsboll T, Krarup T, Madsbad S, et al. Defective amplifica- tion of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002 ;45 ( 8 ) : 1111 - 1119.
4Bagger JI,Knop FK,Lund A,et al. Impaired regulation of theincretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011 ;96(3) :737 -745.
5Oh TJ, Kim MY, Shin JY, et ai. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endo- crinol(Oxf) 2014;80(2) :221 -227.
6Vollmer K, Hoist JJ, Bailer B, et ai. Predictors of incretin con- centrations in subjects with normal, impaired, and diabetic glucose tol- erance. Diabetes 2008;57(3) :678 -687.
7Yang SH, Dou KF, Song W[J]. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362 (25) :2425 - 2426 ; author reply 2426.
8Ahren B, Landin-Olsson M, Jansson PA, et ai. Inhibition of dipeptidyl peptidase - 4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 ;89 ( 5 ) :2078 - 2084.
9Brodows RG, Qu Y, Johns D, et ai. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curt Med Res Opin 2008 ; 24 ( 5 ) : 1395 - 1397.
10Heine RJ,Van Gaal LF,Johns D,et ai. Exenatide versus insu- lin glargine in patients with suboptimaily controlled type 2 diabetes:a randomized trial. Ann Intern Med 2005 ; 143 ( 8 ) :559 - 569.
